APPLIED GENETIC TECHNOLOGIES CORP Form 8-K February 24, 2015

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 24, 2015

Applied genetic technologies corporation

(Exact Name of Registrant as Specified in Charter)

Delaware001-3637059-3553710(State or other jurisdiction(Commission (IRS Employer))

of incorporation) File Number) Identification Number)

11801 Research Drive

Suite D

Alachua, Florida 32615

(Address of principal executive offices) (Zip Code)

(386) 462-2204

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 8-K

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 8-K

Item 7.01 Regulation FD Disclosure.

A copy of the Company's current investor presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. A copy of the investor presentation is also available on the Company's website.

In accordance with General Instruction B.2 of Form 8-K, the information contained in Item 7.01 of this Current Report on Form 8-K, including the Exhibit attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Investor presentation entitled "Visionary Science for Life Changing Cures 2015."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

APPLIED GENETIC TECHNOLOGIES CORPORATION

By:/s/ Lawrence E. Bullock Lawrence E. Bullock Chief Financial Officer

Date: February 24, 2015

Exhibit Index

Exhibit No. Description

99.1 Investor presentation entitled "Visionary Science for Life Changing Cures 2015."

3